Evinacumab for Homozygous Familial Hypercholesterolemia
The New England Journal of Medicine
Recently released results from a clinical trial reported the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks, in patients with homozygous familial hypercholesterolemia.